Iaccheri B, Fiore T, Papadaki T et al.
Massachusetts Eye Research and Surgery Institute, Cambridge, MA, USA.
Clin Ther 2008;30:2069–74.
Editor’s note: This study included 55 patients who had received a variety of therapies for ocular toxoplasmosis: clindamycin, sulfadiazine, pyrimethamine, trimethoprim-sulfisoxazole, and atovaquone, alone or in combination. Adverse drug reactions were common (40%), most often involving a rash with sulfadiazine or gastrointestinal problems such as diarrhea,stomach upset, and bleeding with clinda-mycin. There were two serious adverse drug reactions: gastrointestinal bleeding in a patient on clindamycin and leukopenia in a patient treated with pyrimethamine. Considering the dubious role of systemic therapy in the treatment of toxoplasmosis, these adverse effects suggest that clinicians should exercise caution in the application of such therapy.